- Sales and EBIT further increased
- EBITDA at 26.6% and EBIT at 17.9% of sales
- Net profit affected by currency effects
- Capacity expanded and new jobs created
- Stronger second semester expected
- Fiscal 2017 expected to be a very good year
- Full-year guidance confirmed
Bubendorf/Basel, August 25, 2017 – Bachem Group (SIX: BANB) increased its sales in the first half of 2017 by 5.3% to a new record high of 119.5 million CHF (H1 2016: 113.4 million CHF). In contrast to the previous year, exchange rate movements did not have a relevant impact on the translation of local sales, which were up by 5.2% year-on-year. Generics sales reached 52.0 million CHF and were slightly below the very strong level achieved during the prior year period (53.9 million CHF). There were promising developments in the research ingredients product line. Catalog peptides and custom synthesis products performed well in the face of a challenging, highly competitive market environment. Bachem’s New Chemical Entities (NCEs) product line delivered outstanding results again, with sales advancing about 24% year-on-year. Despite some project delays and temporarily reduced cost absorption due to capacity expansions, operating profit increased to 31.7 million CHF at the EBITDA level and to 21.4 million CHF at the EBIT level. Currency translation effects of -2.7 million CHF had a clearly negative impact on net profit for the first half 2017. This is largely attributed to the valuation at the balance sheet date of USD loans granted to subsidiaries by the holding company. Due to this negative effect, net profit for the period came in at 15.8 million CHF (H1 2016: 17.1 million CHF).